drugset / Trial / NCT00422123

Phase 3 /Seroquel SR Acute Mania Monotherapy - US

NCT00422123

Phase 3 Completed 447 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of sustained-release quetiapine fumarate (Seroquel®) in the treatment of patients with Acute Bipolar Mania for 3 weeks. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Timeline

Start
2007-01
Primary completion
Completion
2007-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Quetiapine Small molecule 400 mg
Subject Quetiapine Small molecule 800 mg